Brainstorm Cell Therapeutics Inc. (BCLI) Social Stream
BRAINSTORM CELL THERAPEUTICS INC (BCLI) Price Targets From Analysts
Use the tables below to see what analysts covering BRAINSTORM CELL THERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-06 | 2 | $12 | $11 | $11.5 | $0.285 | 3935.09% |
| 2021-11-17 | 1 | $12 | $11 | $11.5 | $0.285 | 3935.09% |
| 2021-11-26 | 1 | $11 | $8 | $9.5 | $0.285 | 3233.33% |
| 2021-12-13 | 1 | $14 | $8 | $11 | $0.285 | 3759.65% |
| 2022-05-24 | 1 | $14 | $8 | $11 | $0.285 | 3759.65% |
| 2022-08-17 | 1 | $21 | $8 | $14.5 | $0.285 | 4987.72% |
| 2022-11-18 | 1 | $9 | $5 | $7 | $0.285 | 2356.14% |
| 2023-03-27 | 1 | $20 | $5 | $12.5 | $0.285 | 4285.96% |
| 2023-09-26 | 1 | $20 | $10 | $15 | $0.285 | 5163.16% |
| 2023-12-08 | 1 | $0.5 | $0.5 | $0.5 | $0.285 | 75.44% |
Price Target Last Issued September 26, 2023
The Trend in the Analyst Price Target
BCLI's average price target has moved down $10.5 over the prior 20 months.
Over the past 37 weeks, BCLI's average upside potential has been 1,056.35%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-04-04 | 1 | 20.0 | 10.0 | 15.0 | 2.670 | 461.8% |
| 2023-09-26 | 1 | 20.0 | 10.0 | 15.0 | 0.392 | 3726.53% |
| 2023-09-26 | 1 | 20.0 | 20.0 | 20.0 | 0.392 | 5002.04% |
| 2023-11-16 | 1 | 0.5 | 0.5 | 0.5 | 0.176 | 184.09% |
| 2023-12-08 | 1 | 0.5 | 0.5 | 0.5 | 0.200 | 150% |
BCLI Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3 | 0 | 0 | 1 | 0 | 0 | 1 |
The Trend in the Broker Recommendations
Over the past 25 months, BCLI's average broker recommendation rating worsened by 2.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BCLI as an investment opportunity.
- In the context of all US stocks, BRAINSTORM CELL THERAPEUTICS INC's number of analysts covering the stock is higher than 5.66% of them.
- BRAINSTORM CELL THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 1069.96% of all US stocks.
- BRAINSTORM CELL THERAPEUTICS INC's average analyst price target is higher than 216.36% of Healthcare stocks.
- BCLI has a lower variance in analysts' estimates than -397.96% of stocks in the small market cap category.
In the Pharmaceutical Products industry, ATHA, VOR, and ACHL are the three stocks most similar to BRAINSTORM CELL THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is BCLI a Buy, Hold or Sell? See the POWR Ratings now!